| Literature DB >> 27427486 |
Jia Yu Wang1, Lei Jin2, Xu Guang Yan1, Simonne Sherwin1, Margaret Farrelly1, Yuan Yuan Zhang1, Fen Liu1, Chun Yan Wang1, Su Tang Guo1, Hamed Yari1, Ting La1, Jennifer McFarlane1, Fu Xi Lei1, Hessam Tabatabaee1, Jie Zhong Chen1, Amanda Croft1, Chen Chen Jiang2, Xu Dong Zhang3.
Abstract
The effect of MTH1 inhibition on cancer cell survival has been elusive. Here we report that although silencing of MTH1 does not affect survival of melanoma cells, TH588, one of the first-in-class MTH1 inhibitors, kills melanoma cells through apoptosis independently of its inhibitory effect on MTH1. Induction of apoptosis by TH588 was not alleviated by MTH1 overexpression or introduction of the bacterial homolog of MTH1 that has 8-oxodGTPase activity but cannot be inhibited by TH588, indicating that MTH1 inhibition is not the cause of TH588-induced killing of melanoma cells. Although knockdown of MTH1 did not impinge on the viability of melanoma cells, it rendered melanoma cells sensitive to apoptosis induced by the oxidative stress inducer elesclomol. Of note, treatment with elesclomol also enhanced TH588-induced apoptosis, whereas a reactive oxygen species scavenger or an antioxidant attenuated the apoptosis triggered by TH588. Indeed, the sensitivity of melanoma cells to TH588 was correlated with endogenous levels of reactive oxygen species. Collectively, these results indicate that the cytotoxicity of TH588 toward melanoma cells is not associated with its inhibitory effect on MTH1, although it is mediated by cellular production of ROS.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27427486 DOI: 10.1016/j.jid.2016.06.625
Source DB: PubMed Journal: J Invest Dermatol ISSN: 0022-202X Impact factor: 8.551